Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer
Conditions
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Conditions: official terms
Breast Neoplasms
Conditions: Keywords
Breast, Cancer, Human Epidermal Growth Factor 2 (Her2), irradiation
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Case-Only, Time Perspective: Prospective
Overall Status
Recruiting
Summary
Based on fundamental study (in Vitro and in Vivo, Pro. Jianjian Li), Her2 expression would be changed from negative to positive by cancer irradiation with liner-accelerator at dose 6GY or up. The propose of this study is to reveal the irradiation result on Her2 expression in human breast cancer.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 80 Years
Minimum Age: 18 Years
Gender: Female
Criteria: Inclusion Criteria:

- histological confirmed advanced breast cancer

- cancer sample can be obtained by fine needle biopsy

- IHC and FISH confirmed Her2 negative

- radiotherapy indication for local residual cancer

Exclusion Criteria:

- no radiotherapy indication

- patient refuse
Location
Qingdao Central Hospital, Qingdao Cancer Hospital
Qingdao, Shandong, China
Status: Recruiting
Contact: youxin ji, M.D. - 8653268665078 - mdji001@gmail.com
Start Date
August 2013
Completion Date
December 2015
Sponsors
Qingdao Central Hospital
Source
Qingdao Central Hospital
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page